Show simple item record

dc.contributor.authorClay, F.*
dc.contributor.authorHicks, A.*
dc.contributor.authorZaman, Hadar*
dc.contributor.authorPonsford, J.*
dc.contributor.authorBatty, R.*
dc.contributor.authorPerry, L.*
dc.contributor.authorHopwood, M.J.*
dc.date.accessioned2019-02-25T10:00:27Z
dc.date.available2019-02-25T10:00:27Z
dc.date.issued2019
dc.identifier.citationClay F, Hicks A, Zaman H et al (2019) Prophylaxis pharmacotherapy to prevent the onset of post traumatic brain injury depression: a systematic review. Journal of Neurotrauma. 36(13): 2053-2064.en_US
dc.identifier.urihttp://hdl.handle.net/10454/16839
dc.descriptionYesen_US
dc.description.abstractBackground: Depression is a common psychiatric problem following traumatic brain injury (TBI) with reported prevalence rates of 30-77% in the first year post-TBI. Given the negative influence of post-TBI depression on cognition, interpersonal, social, physical and occupational functioning; early initiation of pharmacotherapy to prevent post-TBI depression has been considered. This systematic review will synthesize the available evidence from published studies on the effectiveness and harms of pharmacotherapy for the secondary prevention of post-TBI depression. Method: Studies published before November 2017 were reviewed. Six databases were searched, with additional searching of key additional documents. Studies meeting inclusion criteria were evaluated for methodological quality. Results: Six articles addressing five studies met inclusion criteria. Study designs included three randomised controlled trials (RCT), two retrospective cohorts and one case-control. Prophylactic pharmacotherapy included antidepressants, beta-blockers and statins. In one RCT, the number-needed-to-treat with sertraline to prevent one case of depression post-TBI at 24 weeks was 5.9 (95%CI: 3.1-71.1). Prescribing beta-blockers prior to TBI reduced the depression risk regardless of the specific brain trauma. TBI patients with pre-existing hyperlipidemia not treated with statins had an increased depression risk compared to those without hyperlipidemia. Conclusion: Early initiation of sertraline prophylaxis in nondepressed TBI patients shows promise to reduce the odds of post-TBI depression developing. However, in the absence of rigorous study of tolerability, existing data are insufficient to recommend sertraline prophylaxis. Optimal timing and treatment duration with identification of patients most likely to benefit from prophylaxis require further consideration. Dedicated prospective studies assessing the effects of beta-blockers and statins on post-TBI depression are required.en_US
dc.description.sponsorshipThe Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR) at Monash University, provided funding for this review.en_US
dc.language.isoenen_US
dc.rights© 2019 Final publication is available from Mary Ann Liebert, Inc., publishers https://doi.org/10.1089/neu.2018.6244.en_US
dc.subjectTraumatic brain injuryen_US
dc.subjectTBIen_US
dc.subjectPharmacotherapyen_US
dc.subjectDepressionen_US
dc.titleProphylaxis pharmacotherapy to prevent the onset of post traumatic brain injury depression: a systematic reviewen_US
dc.status.refereedYesen_US
dc.date.Accepted2019-01-17
dc.date.application2019-01-17
dc.typeArticleen_US
dc.type.versionAccepted manuscripten_US
dc.identifier.doihttps://doi.org/10.1089/neu.2018.6244


Item file(s)

Thumbnail
Name:
Zaman_2019.pdf
Size:
478.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record